Plain-English translation of NCT05100069 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety study of , a tablet taken daily to treat advanced lung cancer in Japan. The research team will monitor you for one year to watch for any side effects, especially those affecting your lungs. You'll take the medication as part of your regular cancer care, and doctors will keep track of how you're doing.
is used to treat a specific type of lung cancer, and this study exists to carefully document what side effects occur in real-world use and make sure it's safe for patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily as prescribed by your doctor—starting with a lower dose for the first week, then moving to the regular dose for the remaining 51 weeks. Your clinic will record information about any side effects you experience during the year of treatment. You'll continue receiving your regular cancer care while the study team documents how the medication affects you.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Japan
Enrollment target
~500 participants
Started
November 2021
Primary completion
September 2030
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Takeda Contact
Takeda
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.